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ABSTRACT:
The biguanide metformin, a widely used drug for the treatment of type 2 diabetes, 
may exert cancer chemopreventive effects by suppressing the transformative and 
hyperproliferative processes that initiate carcinogenesis. Metformin’s molecular 
targets in cancer cells (e.g., mTOR, HER2) are similar to those currently being 
used for directed cancer therapy. However, metformin is nontoxic and might be 
extremely  useful  for  enhancing  treatment  efficacy  of  mechanism-based  and 
biologically targeted drugs. Here, we first revisit the epidemiological, preclinical, 
and clinical evidence from the last 5 years showing that metformin is a promising 
candidate for oncology therapeutics. Second, the anticancer effects of metformin 
by both direct (insulin-independent) and indirect (insulin-dependent) mechanisms 
are discussed in terms of metformin-targeted processes and the ontogenesis of 
cancer stem cells (CSC), including Epithelial-to-Mesenchymal Transition (EMT) and 
microRNAs-regulated dedifferentiation of CSCs. Finally, we present preliminary 
evidence that metformin may regulate cellular senescence, an innate safeguard 
against cellular immortalization. There are two main lines of evidence that suggest 
that metformin’s primary target is the immortalizing step during tumorigenesis. 
First, metformin activates intracellular DNA damage response checkpoints. Second, 
metformin attenuates the anti-senescence effects of the ATP-generating glycolytic 
metabotype-the Warburg effect-, which is required for self-renewal and proliferation 
of CSCs. If metformin therapy presents an intrinsic barrier against tumorigenesis 
by lowering the threshold for stress-induced senescence, metformin therapeutic 
strategies may be pivotal for therapeutic intervention for cancer. Current and 
future clinical trials will elucidate whether metformin has the potential to be used 
in preventive and treatment settings as an adjuvant to current cancer therapeutics.
DIABETES AND CANCER: FROM 
EPIDEMIOLOGY TO CELL BIOLOGY
In the relevant medical literature, type 2 diabetes 
has been linked to an increased risk of developing liver, 
pancreatic, colorectal, endometrial, kidney, urinary 
bladder and breast cancer as well as non-Hodgkin’s 
lymphoma [1-4]. However, men with diabetes mellitus 
have a slightly lower risk of developing prostate cancer 
than average [5]. Moreover, the impact of type 2 diabetes Oncotarget 2011; 2:  896 - 917 897 www.impactjournals.com/oncotarget
on the development of cancer in diabetic patients and the 
specific survival of those patients have most likely been 
underestimated because an estimated 3-5% of the adult 
population is thought to have undiagnosed type 2 diabetes 
[6]. In a recent review and meta-analysis of all-cause 
mortality of patients with pre-existing diabetes, Peairs et 
al. [7] reported that patients with both breast cancer and 
diabetes had a significantly greater risk of death (i.e., 49%) 
compared with their nondiabetic counterparts. Although 
Peairs’ study could be inaccurate due to the fact that over 
40% of people age 20 or older have undiagnosed pre-
diabetes or a delayed diagnosis of diabetes [8], Barone et 
al. [9] similarly observed a statistically significant increase 
in the risk of death in breast, endometrial, colon and 
rectal cancer patients who have diabetes compared with 
nondiabetic cancer patients. In newly diagnosed cancer 
patients, the prevalence of diabetes ranges from 8% to 
18%, and diabetes is significantly associated with breast 
cancer in women [10], regardless of body mass. It should 
be acknowledged, however, that diabetes mellitus is not 
a homogeneous disease. Most studies on cancer patients 
have included patients with type 2 diabetes in part because 
of its high prevalence (i.e., 90% of all diabetes patients 
have type 2 diabetes) and because cancer is predominantly 
a disease of the elderly, a stage in life when type 2 diabetes 
is more frequent. Type 2 diabetes has metabolic and 
hormonal characteristics that differ from those in type 1 
diabetes. Additionally, hyperglycemia and endogenous 
hyperinsulinemia can coexist for a long period, including 
during pre-diabetes. Importantly, strong evidence points 
toward insulin resistance and associated mitogenic 
hyperinsulinemia as a direct pathway connecting diabetes, 
obesity and metabolic syndrome with cancer. 
MOLECULAR LINKS BETWEEN 
DIABETES AND CANCER (I): INSULIN 
RECEPTORS
The membrane-bound receptor of insulin (IR) is a 
heterotetrameric protein that consists of four subunits; 
two subunits protrude from the cell surface and bind 
insulin, and the other two subunits span the membrane and 
protrude into the cytoplasm. Insulin binds to its receptor 
on the cell surface, causing a conformational change in the 
membrane-spanning subunits, which have tyrosine kinase 
activity. There are two isoforms of the IR, namely IR-A 
(also called fetal IR) and IR-B, which are produced by 
alternative splicing. The IR-A isoform is the predominant 
form in cancer cells because it can elicit mitogenic 
rather than metabolic effects [11]. Insulin-like growth 
factor 1 receptor (IGF-1R), which shares approximately 
60%  homology  with  IR,  is  a  transmembrane  tyrosine 
kinase  activated  by  the  binding  of  its  ligand  (IGF-1) 
and promotes mitogenic, metastatic, and anti-apoptotic 
phenotypes  in  breast  cancer.  The  insulin  and  IGF-1 
pathways are closely intertwined because both ligands 
can bind with different affinities the IR or the IGF-1R. 
Therefore, the activation of both receptors by insulin leads 
to the induction of two major intracellular transduction 
cascades, resulting in growth and enhanced survival. 
The survival pathway involves multiple anti-apoptotic 
targets  of  the  phosphatidylinositol  3-kinase  (PI-3K)/
serine/threonine kinase AKT signaling pathway, and the 
proliferation pathway involves activation of the mitogen-
activated kinases MEK and ERK [4].
MOLECULAR LINKS BETWEEN 
DIABETES AND CANCER (II): INSULIN 
RESISTANCE AND METABOLIC 
SYNDROME
Insulin resistance in type 2 diabetic patients is 
a consequence, at least in part, of the upregulation of 
cytokines and free fatty acid derivatives that activate the 
inflammatory cascade and protein kinase C-zeta (PKC-
zeta),  a  serine/threonine  kinase  that  acts  downstream 
of the PI-3K and insulin signaling pathways. PKC-zeta 
phosphorylates insulin receptor substrate-1 (IRS-1) and 
impairs the ability of IRS-1 to activate PI-3K in response 
to insulin [12]. Because PKC-zeta is located downstream 
of  IRS-1  and  PI-3K  in  established  insulin  signaling 
pathways,  PKC-zeta  may  participate  in  a  negative 
feedback pathway that promotes hyperglycemia. It should 
be noted that in contrast to type 1 diabetic patients, insulin 
resistance in patients with type 2 diabetes does not involve 
the “proliferation/mitogenic” pathway. As a consequence, 
the administration of exogenous insulin or insulin-
mimetic compounds to type 2 diabetic patients might 
hyperactivate IR-driven mitogenic signaling, increasing 
the overall cancer risk in these patients. Activation of the 
IGF-1R by insulin can also significantly contribute to an 
increased risk of cancer in patients with type 2 diabetes. 
Additionally, obesity is linked with diabetes and cancer 
and increases the incidence of colon, esophageal and 
breast carcinomas. While type 2 diabetes is linked with 
obesity, which increases insulin resistance and accelerates 
diabetes progression [13, 14], insulin resistance leads to 
an enhanced sensitivity to the mitogenic effects of insulin, 
leading to a poorer prognosis in breast cancer patients. 
Metabolic syndrome includes the following risk 
factors: high blood pressure, insulin resistance, obesity 
(especially abdominal obesity), and dyslipidemia. After 
following postmenopausal breast cancer patients who had 
not received chemotherapy, Pasanisi et al. [15] concluded 
that the risk of recurrence increased three-fold in women 
suffering from metabolic syndrome. Flanagan et al. [16] 
recently observed that metabolic syndrome was linked to a 
poor prognosis and overall survival in men with recurrent 
or newly diagnosed metastatic prostate cancer. Thus, 
metabolic syndrome is associated with a shorter time to Oncotarget 2011; 2:  896 - 917 898 www.impactjournals.com/oncotarget
the development of castration-resistant prostate cancer.
METFORMIN: FROM DIABETES TO 
CANCER 
Anti-diabetic metformin: A definition
Metformin is a semi-synthetic biguanide with two 
methyl groups attached to the nitrogen nucleus of biguanide. 
This compound is derived from the hypoglycemic 
substance galegine, which is found naturally in goat’s 
rue (Galega officinalis). Additionally, metformin is used 
to stimulate the activity of the mammary glands and is a 
diuretic used as an adjuvant for the treatment of diabetes. 
Metformin has been approved for use in the treatment 
of hyperglycemia, polycystic ovarian syndrome (PCOS) 
and metabolic syndrome. After oral administration, it 
is absorbed into the body within 1-3 hours, and 90% is 
eliminated by the renal system. Metformin decreases 
glucose absorption in the intestine and glucose production 
in the liver but does not stimulate insulin secretion. 
Consequently,  it  increases the uptake  and  utilization 
of glucose by skeletal muscle and adipose tissues. The 
lowering of blood glucose levels by metformin is only 
observed in people with diabetes and insulin resistance 
but has no effect on healthy people, except those who 
have been subjected to prolonged fasting. Metformin also 
increases the affinity of the insulin receptor for insulin, 
reduces hyperinsulinemia and improves insulin resistance. 
Several days after administering the drug, insulin levels 
are reduced by 25-33% in both diabetic and nondiabetic 
patients. Metformin can also decrease fatty acid uptake 
and oxidation in skeletal muscle cells while lowering 
circulating levels of total cholesterol, Low-density 
lipoprotein  (LDL)  and triglycerides. Additionally, in 
contrast to sulfonylureas, metformin promotes weight loss 
(approximately 2 kg), and once weight loss is achieved, 
weight loss is maintained. Generally, metformin is well 
tolerated, with only 5% of patients being intolerant. 
Its side effects are mild and reversible gastrointestinal 
disorders (30%); metallic taste (3%), which is reversible 
with continued use, and decreased levels of B12 in 6% of 
patients after 29 weeks. Metformin is a safe drug with a 
low risk of lactic acidosis, which affects 3 out of 100,000 
people per year (50% of which are fatal). Renal failure, 
congestive heart failure and an age greater than 80 years 
are factors associated with the highest risk group.
Between June 2010 and June 2011, 31 reviews 
were indexed in PubMed on “metformin and cancer.” A 
recent review published in Clinical Science discussed the 
implications of hyperinsulinemia and insulin resistance in 
the development and progression of cancer [17]. Here, we 
will report the most relevant publications supporting the 
potential benefit of metformin as a novel multi-faceted 
drug to prevent and treat cancer. These studies justify 
the need for clinical trials to confirm the potential anti-
neoplastic activity of metformin, as the preclinical and 
clinical evidence currently available for standard practice 
is largely lacking (Fig. 1). 
Metformin and cancer: Epidemiological evidence
Many studies have found a lower incidence of and 
mortality from cancer in diabetic patients who have been 
treated with metformin. Examples include the large, 
retrospective study by Bowler et al. [18] that involved 
patients who had been treated with either metformin 
or sulfonylurea for a period of at least 5 to 5.5 years. 
This group determined that metformin was associated 
with lower overall mortality (3.5% versus 4.9% for the 
sulfonylurea cohort) and mortality as a result of cancer (an 
HR of 1 for metformin and no insulin use versus an HR 
of 1.3 (CI 1.1-1.6) for the sulfonylurea group). A Dutch 
labor prospective observational trial recently followed 
patients who had used metformin and other anti-diabetic 
agents  for  9.6  years  [19].  In  total,  1300  patients  were 
followed; 289 had been treated with metformin, and 1064 
had been treated with another drug. This group found that 
metformin use was associated with lower mortality due to 
cancer with an adjusted hazard ratio of 0.43 (95% CI 0.23-
0.80), and this association was dose-dependent, resulting 
in a 42% probability of mortality due to cancer for every 
1 g increase in the metformin dose. Additionally, Currie 
et al. [20] observed a decrease in the diagnosis of cancer 
in patients taking insulin and metformin. Another meta-
analysis found a 31% reduction in the cancer rate in patients 
taking metformin and found that this relationship was also 
dose-dependent [21]. In a retrospective study of type 2 
diabetic patients, Evans et al. [22] found reduced cancer 
rates in patients who had been treated with metformin, and 
this relationship was again dose-dependent. In this study, 
the cancer incidence decreased more than 50% (adjusted 
odds ratio of 0.56; 95% CI of 0.43-0.74) if the patients had 
been treated with metformin for more than 4 years.
The treatment of type 2 diabetic patients with 
metformin has also been reported to lower mortality due 
to several solid tumor types. Although little is known 
about the effect of metformin on human colorectal 
carcinogenesis, recent epidemiological studies have 
shown reduced incidence of colorectal cancer in patients 
with type 2 diabetes taking metformin when compared 
with those patients who do not take metformin [20, 23-
25]. Patients with colorectal and pancreatic carcinomas 
who had been treated with metformin showed a 30% 
improvement in survival when compared with patients 
who had been treated with other anti-diabetic treatments 
[25-27]. In patients with hepatocellular carcinomas 
who had been treated with radiofrequency, diabetes was 
associated with lower survival rates versus nondiabetic 
patients, but metformin users had better survival Oncotarget 2011; 2:  896 - 917 899 www.impactjournals.com/oncotarget
outcomes (adjusted hazard ratio of 0.24; 95% CI of 0.07-
0.80) [28]. More importantly, treatment with drugs other 
than metformin and a tumor size larger than 2.5 cm were 
independent variables associated with lower survival rates 
in the entire studied population. Early epidemiological 
studies suggested an inverse relationship between diabetes 
and prostate cancer [5, 29, 30]. Accordingly, a 44% risk 
reduction of prostate cancer incidence in Caucasian men 
on metformin therapy has been reported in a population-
based case-control study [31]. However, Patel et al. [32] 
recently reported that metformin use does not have a 
significant beneficial effect after prostate cancer diagnosis. 
Recently,  a  retrospective  study  published  by 
Jiralerspong et al. [33] showed an increase in the 
effectiveness of neoadjuvant chemotherapy in breast 
cancer patients who took metformin concomitantly with 
systemic therapy in patients with and without diabetes. 
Specifically, diabetic patients who had been treated with 
metformin had a pathologic complete response (pCR) rate 
three times higher (24%) than those who had not been 
treated with metformin (8%). Importantly, the rate of pCR 
in patients without diabetes was 16%. Although metformin 
use has been shown to associate with a decreased risk of 
breast cancer in the long term [34, 35], the overall survival 
rate was the same as in nondiabetic women despite a 
higher  pCR  rate  in  the  metformin-treated  group  [33]. 
Bayraktar et al. [36] observed that triple negative breast 
cancer patients who did not receive adjuvant metformin 
and nondiabetic patients tended to have a higher risk of 
distant metastases compared with the metformin-treated 
group. Their findings, however, suggest that metformin 
use during adjuvant chemotherapy does not significantly 
impact survival outcomes in diabetic patients with highly 
aggressive triple receptor-negative breast cancer. In the 
first line of chemotherapy treatment for advanced lung 
cancer, diabetic patients who were being treated with 
metformin demonstrated better overall survival and 
longer progression-free survival and disease control [37]. 
Although diabetes is associated with a lower incidence 
of prostate cancer, mortality from prostate cancer is 
higher  in  type  2  diabetic  patients  [38].  Recently,  the 
MD Anderson Cancer Center presented a retrospective 
study of 233 diabetic patients with prostate cancer. This 
multivariate analysis analyzed obesity, PSA, grade, age, 
and use of diabetes drugs and showed that treatment 
with  thiazolidinedione  and  metformin  were  significant 
predictors of improved survival (HR: 0.45 and 95% CI: 
0.21-0.9; HR: 0.55 and 95% CI: 0.31-0.96, respectively) 
[39].
Anti-tumor effects of metformin: Molecular 
mechanisms
Although the abovementioned epidemiological 
studies have provided relatively consistent results 
suggesting that people with type 2 diabetes receiving 
metformin demonstrate a lower risk and improved 
outcomes with most common cancers, caution is needed 
when directly translating these findings to clinical cancer 
prevention and treatment. Most of these studies were 
retrospective, clinical, or hospital based and, therefore, 
susceptible to selection bias. For instance, several studies 
did not exclude individuals with prior cancers; moreover, 
patients who received metformin significantly differed in 
many key factors from those who did not receive the drug 
closely related to cancer risk, including age, obesity, and 
smoking history. Despite these methodological limitations, 
both  the  epidemiological  findings  and  the  suspected 
anti-cancer effects of metformin have contributed to the 
interesting hypothesis that metformin may exert clinically 
relevant effects in the primary and secondary prevention of 
human carcinomas. The anti-cancer effects of metformin 
based upon its dual action on systemic insulinemia (i.e., 
maintaining glucose levels and insulin at physiological 
levels in the plasma) and its direct, targeted action against 
cancer cells (with pleiotropic inhibitory effects on multiple 
pathways involved in survival and metastasis) [40] need 
to be further studied. 
Metformin and the ATM/LKB1/AMPK axis
Metformin largely exerts its effects by activating 
5’  adenosine  monophosphate  (AMP)-activated  protein 
kinase  (AMPK).  AMPK  is  a  major  metabolic  sensor 
involved in regulating cellular energy homeostasis. In 
conditions  of  cellular  stress  (e.g.,  glucose  deprivation, 
hypoxia, oxidative stress, or ischemia), the ratio of AMP/
ATP increases, which induces the activation of AMPK. 
Once activated, AMPK inhibits anabolic processes that 
require energy and activates catabolic processes that 
produce  energy.  The  activation  of AMPK  is  mediated 
by  other  proteins  including  the  enzymes  LKB1  (i.e., 
the serine-threonine kinase STK11), CaMKK (calcium/
calmodulin-dependent protein kinase) and TAK1 (TGF-
β-activated protein kinase 1) [41-44]. Indeed, the tumor 
suppressor LKB1 (one of the most commonly mutated 
genes  in  lung  and  pancreatic  cancers  and  melanomas) 
can mediate the action of metformin on AMPK activity 
[45-47]. The absence or decreased expression of LKB1 
in human breast carcinomas is associated with poor 
prognosis [48], which suggests that the inhibition of 
tumorigenesis by metformin may depend on the status of 
LKB1 [49]. However, a recent study in mice found that 
hyperinsulinemia-mediated loss and/or mutation of LKB1 
is a predictor of sensitivity to metformin [50]. 
A polymorphism in the LKB1 gene is associated 
with ovulatory response to treatment of Polycystic 
Ovarian  Syndrome  (PCOS)  patients  with  metformin 
alone in a prospective randomized trial [51]. Additionally, 
genetic polymorphisms in the cell surface transporter 
organic cation transporter 1 (OCT1), which is required Oncotarget 2011; 2:  896 - 917 900 www.impactjournals.com/oncotarget
for the efficient action of metformin, have been shown 
to underlie metformin resistance in some patients with 
type 2 diabetes and PCOS [52-54]. Although it is likely 
that OCT gene polymorphisms may significantly affect 
the  efficacy  and  toxicity  of  metformin  against  human 
cancer cells [55], this remains to be confirmed. Recently, 
a region in the ATM gene (ataxia telangiectasia, mutated) 
that modulates the response to metformin in type 2 
diabetic patients was discovered [56-58]. ATM is a tumor 
suppressor gene implicated in DNA repair and cell cycle 
control. The authors of this study concluded that ATM is 
required for the full anti-glycemic activity of metformin. 
ATM  phosphorylates  LKB1  and  other  components  of 
the insulin pathway but can also modulate the activation 
status  of  AMPK  independent  of  LKB1  [59-61].  This 
suggests  that  an  unexpected  relationship  with  DNA 
repair pathways may explain, at least in part, metformin’s 
efficacy against cancer cells. Using cultured tumor cells, 
we recently confirmed that metformin promotes activation 
of ATM and ATM targets, such as the protein kinase 
Chk2, suggesting a causal linkage between metformin’s 
mechanism of action and metformin’s cancer preventative 
effects [62].
Metformin and endogenous lipogenesis
  One of the consequences of AMPK activation is 
the inhibition of lipogenesis in malignant lesions. Tumor 
cells require high levels of de novo fatty acid synthesis, 
and the most aggressive phenotypes of breast cancer 
have a high rate of lipid metabolism also dependent on 
and involved in proliferation and cell survival [63-65]. 
Furthermore,  tumor  induction  by  certain  oncogenes 
causes  the  activation  and  expression  of  enzymes  for 
the de novo synthesis of fatty acids such as acetyl-CoA 
carboxylase  (ACC)  and  fatty  acid  synthase  (FASN). 
Notably, inhibition of exacerbated lipogenic metabolism 
in tumor cells might result in inhibition of the activity and 
expression of upstream oncoproteins [66-68]. The effects 
of metformin on energy homeostasis in normal and cancer 
cells have been characterized by the blocked activation 
or  expression  of  key  fatty  acid  biosynthesis  enzymes 
(e.g., ACC, FASN, HMGCR) and enhanced expression 
of regulators of mitochondrial biogenesis (e.g., PCG-1α) 
[69-74]. Together, these effects on energy homeostasis are 
expected to significantly contribute to the antiproliferative 
activity of metformin by inhibiting endogenous fatty 
acid biosynthesis and shifting cellular bioenergetics to 
catabolism. Such changes in lipid metabolism have been 
demonstrated  experimentally  using  several  FASN  and 
ACC blockers to inhibit growth and induce apoptotic cell 
death in cancer cells [75-77]. 
Metformin and mammalian target of rapamycin 
(mTOR)
mTOR  is  involved  in  regulating  cellular  energy 
homeostasis by modulating the activity of different 
cellular processes such as protein synthesis and autophagy 
[78-80]. mTOR plays a critical role in cell growth and 
tumorigenesis in different tumors, and its activation 
correlates with cancer progression, adverse prognosis 
and resistance to chemotherapy and molecularly-targeted 
therapies  [81-84].  mTOR  activation  occurs  frequently 
in breast cancer and results in a poorer prognosis. The 
activated form of AMPK inhibits mTOR activity via the 
phosphorylation and stabilization of the tumor suppressor 
tuberous sclerosis complex 2 (TCS2). As such, metformin 
inhibits  the  mTOR-signaling  pathway  in  an  AMPK-
dependent manner, which may provide an explanation 
of the observed anti-neoplastic actions in breast cancer 
[85-88]. In other tumors where mTOR plays an important 
role, including renal cell carcinomas, a mechanism by 
which metformin inhibits tumorigenicity via mTOR and 
activation of AMPK has been demonstrated [89]. Based 
on these data, a combination of therapies directed against 
AMPK and the PI3K/AKT/mTOR pathways has emerged 
as an option for the treatment of cancer [82, 90]. The 
combination treatment of temsirolimus and metformin in a 
phase I clinical trial on solid tumors was feasible with only 
one grade 1 hyperglycemia case [91]. It should be noted 
that mTOR inhibition might also occur in the absence of 
AMPK activation, for example, by inhibiting IGF1, the 
insulin receptor and AKT [92]. Therefore, metformin can 
inhibit mTOR by decreasing the levels of insulin or IGF1 
independent of AMPK. 
Metformin and estradiol
Active  AMPK  inhibits  the  expression  of  the 
aromatase gene in breast adipose tissue by decreasing 
the local production of estrogen [93]. Furthermore, obese 
patients with breast cancer exhibit a higher expression 
of this gene and higher levels of estrogen in breast tissue 
as a result of increased plasma leptin synthesis, which is 
caused by obesity. Leptin inhibits AMPK by increasing the 
expression of aromatase; however, adiponectin activates 
AMPK. Therefore, metformin-based treatments aimed at 
activating AMPK and restoring the leptin/adiponectin axis 
may decrease the occurrence of breast cancer in obese 
patients. 
Metformin and the mitotic cell cycle
AMPK is involved in the process of cell division. 
Recent studies from our laboratory have shown that the 
phosphorylated form of AMPK has a space-time dynamic 
during mitosis, as it is located at the centrioles during the 
initial stages and in the constriction ring during the final 
stages of mitosis [94-96]. Metformin also decreases the 
expression of many genes involved in mitosis including Oncotarget 2011; 2:  896 - 917 901 www.impactjournals.com/oncotarget
kinesins, tubulins, histones, auroras and polo-like kinases 
[97].  Therefore,  the  chronic  activation  of  AMPK  by 
metformin alters mitosis, and the severity of these changes 
may depend on the status of p53 [98]. Specifically, chronic 
activation of AMPK leads to the activation of p53 and 
cellular senescence. Inhibiting oxidative phosphorylation 
with metformin has been suggested to increase glycolysis 
and autophagy in cells bearing native p53. Conversely, 
cancer cells with a mutated p53 that have been treated 
with metformin are unable to reprogram metabolism, and 
the cell undergoes apoptosis [99]. 
Metformin and apoptosis: Impact on chemotherapeutic 
efficacy
Metformin increases the cytotoxicity of some 
drugs. In breast and lung cancer cell lines, metformin and 
paclitaxel synergistically induce cell cycle arrest, and the 
combination increases the number of cells in the G2/M 
phase, inhibiting tumor cell proliferation independent of 
LKB1 [100]. Additionally, in ovarian cancer, metformin 
inhibits tumor growth in nude mice in a dose-dependent 
manner and reduces the number of lung metastases, 
proliferation  (determined  by  Ki-67),  vascular  density 
and  angiogenesis  as  measured  by  VEGF  [101].  More 
importantly, the effects were synergistic with cisplatin 
treatment. Lliopoulos et al. [102] also demonstrated 
a synergistic antitumor effect of metformin with 
cisplatin, doxorubicin and paclitaxel in an animal model. 
Additionally, metformin induces both caspase-dependent 
and poly (ADP-ribose) polymerase-dependent cell death 
in breast cancer cells [103].
Metformin and oncogenes: Impact on targeted cancer 
therapy
Metformin treatment has been shown to efficiently 
inhibit endogenous initiation and progression of 
spontaneous mammary tumors in HER2-transgenic mice 
[104, 105]. Additionally, metformin decreases the levels 
of HER2 activity and expression in cell lines in a dose-
dependent manner. At low  doses  (in  the  micromolar 
range),  the  HER2  tyrosine  kinase  activity is blocked, 
but expression levels are not affected [87]. At higher 
concentrations (in the millimolar range), the expression 
of HER2 protein is downregulated [106]. Furthermore, 
the metformin-induced inhibition of HER2 is independent 
of the molecular mechanism that contributes to the 
overexpression  of  HER2  (i.e.,  gene  amplification  or 
transcriptional activation) [106]. Metformin has different 
effects on gene expression depending on whether a cell 
line is HER2-positive or HER2-negative [97]. In HER2-
negative breast cancer cell lines, the expression of genes 
related to mitosis is decreased in response to metformin. 
Meanwhile,  in  HER2-positive breast cancer cell lines 
treated with metformin, genes involved in apoptosis are 
overexpressed. Although ongoing clinical-translational 
research is required to provide evidence for the usefulness of 
therapeutically combining metformin with HER2-targeted 
Figure 1: Metformin and cancer: From phenomenology 
to molecular understanding in less than a decade. 
Since  an  initial  report  by  Evans  et  al.  [22]  revealing  that 
metformin use in people with type 2 diabetes was associated 
with reduced cancer incidence, the hypothesis that metformin 
may have clinically relevant preventive and treatment effects 
in human cancer exploded as an ever-growing research field, as 
scientists discovered mechanistic connections to pivotal cancer 
markers and even cancer stem cells. Amazingly, the molecular 
and clinical breakthroughs in metformin and cancer have taken 
place during only the past decade. Oncotarget 2011; 2:  896 - 917 902 www.impactjournals.com/oncotarget
therapies [107], it is worth mentioning that metformin acts 
synergistically with the anti-HER2 monoclonal antibody 
trastuzumab (Herceptin™) to eliminate stem/progenitor 
cell populations in HER2-gene amplified breast carcinoma 
cells growing as mammospheres [108]. Moreover, 
metformin  treatment  efficiently  reverses  secondary 
resistance  of  HER2-overexpressing  cancer  cells  to  the 
dual  HER1/HER2  tyrosine  kinase  inhibitor  lapatinib 
(Tykerb™)  by  suppressing  pro-survival  pathways  (i.e., 
the anti-apoptotic protein survivin) [109-111].
In  HER2-positive tumors, metformin has a dual 
effect: 1) inhibiting the activity/expression of the HER2 
onco-tyrosine kinase and 2) blocking the action of mTOR, 
a possible mechanism of resistance to trastuzumab [88, 
112]. Additionally, by decreasing the levels of circulating 
insulin and IGF, activation of the IGFR pathway will be 
avoided. Because transactivation of the IGFR pathway is 
a well-recognized mechanism underlying de novo (i.e., 
primary) [113] and acquired (i.e., secondary) [114, 115] 
resistance to anti-HER2 therapies, metformin’s ability to 
simultaneously target HER2, while preventing increased 
IGF-IR signaling may represent a potential therapeutic tool 
in breast carcinomas resistant to HER2-directed therapy. 
In support of this, a recently conducted pre-clinical study 
with trastuzumab-sensitive parental breast cancer cell lines 
(i.e., BT474 and SKBR3) and trastuzumab-resistant breast 
cancer sublines (i.e., BT-474-HR20 and SKBR3-pool2) 
showed  that  metformin  treatment  causes  significantly 
more inhibition of proliferation and clonogenicity in 
trastuzumab-resistant  sublines  via  disruption  of  HER2/
IGF-IR  complexes  (which  are  solely  present  in  the 
resistant sublines) [116]. Importantly, this effect occurred 
without altering HER2 expression or reduction of IGF-IR 
expression or activity in the trastuzumab-resistant but not 
in the sensitive breast cancer cells. The activity of AMPK 
in cardiac cells is associated with stress-induced survival 
in response to cytokines or energy depletion. Thus, the 
concurrent blockage of oncogenic receptors such as 
HER2, while activating AMPK-related catabolic pathways 
with  metformin  would  be  a  highly  efficacious  therapy 
to prevent, delay and/or reverse resistance to the HER2 
inhibitor while decreasing the risk of cardiomyopathy 
[109, 117]. 
METFORMIN: FROM 
EPIDEMIOLOGICAL AND PRE-
CLINICAL EVIDENCE TO CANCER 
PREVENTION 
The ever-growing amount of epidemiological 
evidence on the relationship between metformin usage and 
cancer incidence and mortality among diabetics does not 
necessarily imply a universal chemoprevention effect of 
metformin, especially because it may not have significant 
(if any) effects in nondiabetics. We should acknowledge 
that population studies have mostly been retrospective 
and confined to diabetic patients, in whom factors that 
are relatively unimportant in the general population may 
have significant roles [118]. Indeed, there is still a lack 
of retrospective clinical evidence for antitumor activity 
of metformin in nondiabetic patients. Because an ideal 
strategy for cancer prevention should employ a limited 
course of low-toxicity therapy to suppress premalignant 
lesions in high-risk cancer patients, forthcoming studies 
should focus on the clinical application of metformin 
and/or other metformin-related biguanides as suppressors 
of premalignant lesions in a broad spectrum of tissues. 
Metformin-based, large-scale cancer prevention trials 
would be more justifiable with strict criteria specifying 
high-risk populations in which metformin is expected to 
provide a greater clinical benefit [119, 120]. Metformin’s 
ability to increase the mean lifespan of tumor-free 
mice while simultaneously decreasing the risk of age-
related death underscores its ability to reduce cancer 
incidence among type 2 diabetics. Evans et al. [22] 
reported that the risk of subsequent cancer diagnosis 
was significantly reduced in patients with type 2 diabetes 
receiving metformin and that metformin’s protective 
effect was increased with metformin use (i.e., dose and/
or time of metformin treatment). Furthermore, a recently 
conducted retrospective study reported an impressive 
56% decrease in the risk of breast cancer among diabetics 
receiving metformin when compared with diabetics 
being treated with other anti-diabetic therapies [121]. In 
addition, available data have revealed that reductions in 
cancer mortality related to metformin use are similar in 
magnitude to reductions in cancer incidence, suggesting 
that the anti-cancer effects of metformin largely depend 
on (or are restricted to) its preventive effects [119]. 
Mechanisms of metformin cancer prevention (I): 
Cancer stem cells
Because high levels of IGF-1 and estradiol can favor 
the generation and/or maintenance of mammary tissue-
specific  stem  cells  [122],  pharmacological  measures 
to  enhance  insulin  sensitivity  (e.g.,  metformin)  might 
significantly  reduce  the  risk  of  metastatic  progression 
in premalignant lesions. Breast stem cell niches not 
only support the self-renewal and maintenance of stem 
cell identity but also control stem cell number and 
proliferation [123]. If regulators of niches also function 
as mitogens for the reservoir of undetected, pre-invasive 
breast cancer lesions and/or dormant cancer stem cells 
[CSCs] within premalignant lesions in situ [124, 125]), 
then metformin’s ability to decrease systemic metabolic 
biomarkers including insulin, IGF-1 and estradiol would 
regulate generation and/or maintenance of mammary stem 
cells  and/or  their  niches. As  such,  this  would  regulate 
the number and proliferation rate of tumor progenitors Oncotarget 2011; 2:  896 - 917 903 www.impactjournals.com/oncotarget
residing at premalignant lesions. Evidence for this CSC-
centered hypothesis underlying breast cancer prevention 
by metformin is the observation of increased breast cancer 
risk within 2 years in diabetic women receiving the insulin 
analog glargine [126-128]. Hormonal factors influencing 
the natural history of breast cancer (e.g., insulin, IGF-1, 
estradiol) could have effects in very short amounts of time. 
Therefore, the increased breast cancer risk in glargine users 
likely reflects the growth of subclinical malignant lesions 
to clinically diagnosable volumes rather than the initiation 
of  new  tumors  [129]. As  such,  metformin’s  inhibitory 
effects  on  CSC-like  subpopulations  in  intraepithelial 
neoplasias might prevent invasive carcinomas including 
breast cancer in pre- and post-menopausal women [120, 
130]. 
The  theory  of  CSCs  (also  called  tumor-
initiating  cells)  suggests  that  tumors  consist  of  two 
cell  subpopulations.  CSCs  have  the  capacity  to  self-
renew while giving rise to other distinct phenotypic 
subpopulations upon differentiation, which contributes 
to cellular heterogeneity within human tumors [131-
133]. Presumably, tumor relapse is due to the intrinsic 
chemoresistance  of  CSCs. Therefore,  drugs  that  attack 
both the tumorigenic subpopulation of CSCs and the more 
differentiated and proliferating population could efficiently 
prevent disease recurrence [134, 135]. A landmark study 
that demonstrated the effect of metformin on CSCs was 
conducted by Hirsch et al. [136] using mice with a human 
breast cancer xenograft. Metformin treatment was found 
to specifically eliminate CD44+/CD24-/low CSCs and had 
a synergistic effect with doxorubicin, which resulted in 
reduced tumor burden and delayed tumor recurrence 
and was more effective than either agent alone [136]. 
Furthermore,  metformin  combined  with  doxorubicin/
cisplatin or paclitaxel delayed tumor relapse better than 
either  agent  alone.  Surprisingly,  the combination was 
effective with a four-fold lower dose of doxorubicin, thus 
decreasing the toxicity of chemotherapy and improving its 
efficiency. In this case, metformin could be preventing the 
dedifferentiation of tumor cells to CSCs [102]. 
Given that metformin appears to act on a subpopulation 
of tumor stem cells, it seems reasonable that more 
aggressive breast cancer subtypes enriched with CSC-like 
features, such as basal-like (triple negative) and HER2 
cells, would be more sensitive to the action of metformin 
[88]. Recently, we found that proliferation and size of 
CSC multicellular “microtumors” (i.e., mammospheres) 
in non-adherent and non-differentiating conditions were 
inhibited by metformin, indirectly reflecting metformin’s 
ability to suppress stem cell renewal and progenitor 
cell proliferation, respectively [108]. Perhaps more 
importantly, metformin treatment appears to significantly 
alter  the  genetic  and/or  epigenetic  plasticity  of  CSCs 
because it can resensitize mammosphere-initiating cells 
to HER2-targeted drugs [108]. Furthermore, we recently 
confirmed that among the different molecular classes of 
breast cancer, triple-negative/basal-like breast cancer cells 
are significantly more sensitive to the growth-inhibitory 
effects  of  metformin  [137-139].  In  the  triple-negative 
breast cancers, metformin has been shown to suppress 
the metastasis-associated protein and breast CSC marker 
CD24 [139], suggesting a therapeutic role for metformin-
based regimens in the clinical management of highly 
metastatic subgroups of triple-negative/basal-like breast 
carcinomas naturally enriched with CD24-positive tumor-
initiating cells [140-142]. 
Mechanisms of metformin cancer prevention (II): 
Epithelial-to-mesenchymal transition (EMT) and 
microRNAs
 The EMT has been established as a mechanism for 
the acquisition of stem cell characteristics (self-renewal 
and  tumor  initiation)  [143-147].  Differentiated  cancer 
cells lose their polarity, thus acquiring the properties of 
mesenchymal mobility, which allows a cell to leave the 
epithelial layer through the basal lamina and reach the 
bloodstream, thus permitting metastatic progression. 
Cancer-associated EMT cells lose epithelial characteristics, 
such as the expression of E-cadherin, while acquiring de 
novo expression of mesenchymal-associated genes. In 
breast carcinomas, these cells express the CD44+/CD24-/
low mesenchymal immunophenotype on the cell surface 
[148].  In  highly  metastatic  basal-like  MDA-MB-231 
breast cancer cells, our group has shown that metformin 
treatment  dynamically  suppresses  the  CD44+/CD24-/low 
CSC phenotype via transcriptional repression of the EMT 
machinery  including  Transforming  Growth  Factor-β1, 
ZEB, TWIST and SLUG (SNAIL2) [149]. Metformin-
mediated regulation of E-cadherin can efficiently prevent 
the  TGFβ-induced  conversion  of  epithelial  cells  into 
migratory mesenchymal cells [150]. This treatment 
maintains the location of E-cadherin at sites of cell-cell 
contact and prevents the cellular changes (morphology 
and  size)  associated  with  a  mesenchymal  status. 
Therefore, metformin treatment could be a useful strategy 
to impede the formation of migrating CSCs [120] (Fig. 
2A). We have recently proposed that metformin can alter 
micro(mi)RNA-regulated  cell  differentiation  to  prevent 
the  invasion  of  human  carcinomas.  Invasion/metastasis 
of epithelial carcinomas including breast cancer can be 
viewed as a miRNA lethal-7 (let-7)-regulated continuum 
of progressive dedifferentiation (i.e., EMT) with a cell at 
the endpoint that has stem cell-like properties [151, 152]. 
As such, metformin’s ability to upregulate let-7 expression 
in premalignant cells may efficiently push them to become 
less “embryonic” (i.e., mesenchymal stem-like cells) and 
more  “normal”  (i.e.,  non-stem  differentiated  epithelial 
cells). This could block the dynamic nature of cellular 
transformation and CSC formation in response not only 
to oncogenes but also to the local microenvironment [120, Oncotarget 2011; 2:  896 - 917 904 www.impactjournals.com/oncotarget
153] (Fig. 2B).
MECHANISMS OF METFORMIN IN 
CANCER PREVENTION (III): CELLULAR 
SENESCENCE
  Studies  of  human  cancer  tissues  and  cancer-
prone mice argue strongly that cellular senescence is 
an important physiological mechanism in protecting 
cells against malignant transformation [154-156]. 
Senescent cells can be found abundantly in intraepithelial 
premalignant lesions, whereas senescent cells are scarce 
in invasive, life-threatening metastatic carcinomas, 
supporting the notion that cellular senescence suppresses 
cancer in vivo. Dismantling the senescence response (e.g., 
via  inactivation  of  the  tumor-suppressor  p53)  causes  a 
significant  acceleration  in  the  development  of  human 
tumors, whereas senescence in established malignant states 
is associated with tumor regression [157]. Senescence-
Figure 2: Metformin: A guardian of EMT and micro(mi)RNA-regulated stemness and cancer progression. A. EMT 
Induction of the EMT transdifferentiation program in cancer cells results in the acquisition of invasive and metastatic properties. The 
emergence of CSCs also occurs in part as a result of EMT. In addition, EMT of tumor cells contributes to drug resistance. Figure depicts 
how metformin’s ability to inhibit the EMT transdifferentiation program may represent a therapeutic strategy to clinically overcome 
chemotherapy refractoriness in CSCs-enriched invasive/metastastic carcinomas. B. Two evolutionary conserved families of miRNAs, let-
7 and miR-200, regulate pivotal differentiation processes during development. On the one hand, loss of let-7 in cancer triggers reverse 
embryogenesis and dedifferentiation phenomena. On the other hand, miR-200 has been identified as a powerful regulator of the EMT 
process. The figure depicts how deregulation of let-7 and miRNA-200 during carcinogenesis could each contribute to tumor progression, 
one by controlling let-7 regulated oncofetal genes (LOGs) and, therefore, stem cell maintenance, and the other by regulating EMT and, 
therefore, the generation of migrating CSCs. Obviously, crosstalk exists between loss of let-7 –that results in reverse embryogenesis and 
dedifferentiation- and miR-200-regulated EMT –that results in up-regulation of a number of stem cell markers-. Metformin, through its 
ability to potentiate the expression of let-7a [153] and miR-200 (unpublished observations) and to prevent the overexpression of classical 
EMT markers such as ZEB, TWIST and SLUG (SNAIL2) [149], may function as an efficient molecular guardian against cancer progression 
and/or tumor recurrence after treatment. Oncotarget 2011; 2:  896 - 917 905 www.impactjournals.com/oncotarget
inducing  stressors  such  as  oxidative  damage,  DNA 
damage  and/or  oncogenes  normally  trigger  senescence 
at the premalignant tumor stage [158]. In agreement with 
an active role of cellular senescence in cancer prevention, 
the subsequent invasion of premalignant lesions almost 
inevitably involves one or more events that inhibit or impair 
the senescence pathway. For instance, the convergence of 
EMT-driven acquisition of stem cell characteristics with 
enhanced autophagy in response to bioenergetic stresses 
may turn premalignant phenotypes into tumor-initiating 
cells that bypass metabolic stress- and oncogene-induced 
cellular  senescence  [120,  125,  159-161].  Metformin’s 
ability to enhance senescence in established premalignant 
disease or to trigger cellular senescence in fully malignant 
invasive disease is an unexplored mechanism that may 
explain metformin-mediated cancer prevention and 
treatment. 
Mechanisms of metformin-induced cellular senescence 
(I): Enhanced DNA Damage Response (DDR)-like 
signaling
In  recent  years,  evidence  has  emerged  that  DNA 
Damage Response (DDR) is one of the earliest molecular 
events that impedes the multistep progression of human 
epithelial  carcinomas  to  invasive  malignancy.  DNA 
damage can be due to a variety of factors such as telomere 
dysfunction  and  oncogene-induced  “replication  stress” 
[162-164]. Accordingly, there is a strong selective 
pressure  for  mutation  in  DDR  components  because 
activation of DNA damage checkpoints acts as the innate 
barrier against invasion/metastasis of tumors [162, 165]. 
Because the DDR is a major component of the innate 
tumor suppressor barrier in early human tumorigenesis, 
selective  activation  of  DDR  surveillance  mechanisms 
may therefore directly contribute to metformin’s cancer 
preventive effects. It would be interesting to test whether 
metformin  can  significantly  increase  senescence  in 
premalignant lesions of the skin, the lung, the pancreas 
or the breast. Epithelial cells within premalignant breast 
lesions with markers of senescence maintain an intact 
response to cellular stress and are less likely to develop 
subsequent tumor events. In other words, the presence 
of functional pro-senescence mechanisms is the most 
accurate predictor of recurrence and progression of 
premalignant lesions in situ (e.g. in Ductal carcinoma in 
situ [DCIS] of the breast) to invasive basal-like breast 
carcinomas [166]. This evidence is valuable pre-clinical 
framework for pro-senescence metformin-based anti-
breast cancer therapies, which could be evaluated in DCIS 
xenografts before and during the spontaneous transition to 
invasive breast cancer lesions [167-169]. As such, we are 
currently assessing whether cancer risk with metformin 
treatment is related to its ability to activate DNA damage-
like signaling that induces specific senescence-like growth 
inhibition of premalignant or malignant cells without 
altering the normal function of non-neoplastic tissues. 
Many tumor cells retain the ability to senesce in 
response  to  DNA-damaging  chemotherapeutic  agents 
in culture and in vivo. Because of this, it is tempting to 
suggest that, in the context of DDR, metformin-enhanced 
cellular senescence may underlie metformin’s ability to 
increase the rate of pCR in neoadjuvant chemotherapy in 
diabetic patients with breast cancer [33] and to promote 
tumor regression and prevent relapse when combined 
with suboptimal doses of chemotherapy in animal models 
[102]. In primary murine embryonic fibroblasts from wild-
type (p53+/+) mice, we recently tested whether metformin 
can regulate the senescence-like growth inhibition induced 
by  doxorubicin,  a  DNA-damaging  drug  that  induces 
cell  senescence  at  concentrations  significantly  lower 
than those required for inducing apoptosis. Exposure 
to metformin increased the senescent subpopulations in 
control  (untreated)  cells  and  synergistically  increased 
the cell senescence in response to doxorubicin-induced 
DNA  damage  [161].  It  would  also  be  relevant  to 
evaluate whether metformin facilitates the “accelerated 
senescence” triggered in normal cells by the expression 
of mutated, transforming versions of oncogenes (e.g., Ras 
or Raf) and by some other forms of supraphysiological 
mitogenic signaling irrespective of senescence-
inhibiting  adaptations  (e.g.,  inactivation  of  p53)  [170-
172]. Proliferative invasive cancer cells with activated 
oncogenes acquire instrumental mechanisms to suppress 
senescence in early stages of cancer pathogenesis (e.g., in 
in situ lesions); organisms in which cells fail to undergo 
senescence die prematurely of cancer [173]. Therefore, 
activating the program of senescence in tumor cells is an 
attractive approach to cancer treatment [157, 174] and 
may help to explain the differential impact of metformin 
on cancer incidence in non-prone and cancer-prone animal 
models and perhaps also in cancer-prone individuals. It 
remains to be elucidated, however, whether metformin’s 
ability to strongly activate the ATM/Chk2-regulated DDR 
checkpoint [62] is a critical event that prevents neoplastic 
epithelium to progress unimpeded into invasive cancer in 
individuals without type 2 diabetes. 
Mechanisms of metformin-induced cellular senescence 
(II): Senescence bioenergetics in CSCs
It now appears that metformin can be added 
to the growing list of agents that have potent cancer 
chemopreventive properties by activating DDR signaling. 
Ongoing  experiments  in  our  laboratory  have  shown 
that chronic exposure to metformin drastically reduces 
the  lifespan  of  non-transformed  human  fibroblasts  by 
accelerating replicative cellular senescence (unpublished 
observations).  In  the  presence  of  a  constant  mitogenic 
input, metformin treatment promotes an inappropriate 
culture environment that determines a new threshold 
level of negative signals rapidly surpassed and caused 
accelerated stress-induced senescence. Because culture 
conditions  induce  DNA  damage  in  cultured  human 
fibroblasts, metformin-accelerated replicative senescence Oncotarget 2011; 2:  896 - 917 906 www.impactjournals.com/oncotarget
may mostly rely on the ability of metformin to establish a 
stronger DDR-dependent cell cycle arrest. Alternatively, 
a lower threshold for stress-induced senescence due 
to metformin can be explained in terms of metformin-
regulated energy metabolism. The most widely accepted 
interpretation for the biological function of cellular 
senescence is that it serves as a mechanism for restricting 
cancer progression. Based on this, escaping from cellular 
senescence and becoming immortal constitutes an 
additional step in oncogenesis that most tumors require 
for their ongoing proliferation [175]. Recent studies have 
suggested that the accumulation of reactive oxygen species 
(ROS) and oxidative damage are commonly involved in 
culture stress- or oncogene-induced senescence. Because 
increasing  accumulation  of  ROS  is  observed  during 
replicative senescence (i.e., the replicative potential of both 
murine and human fibroblasts is significantly higher under 
low oxygen), the ability of immortalized cells including 
embryonic stem cells, induced pluripotent stem cells 
(iPSCs) and CSCs to buffer oxidative stress may be pivotal 
for explaining their immortality [176-179]. Early studies 
by Warburg [180] found that most cancer cells metabolize 
glucose by enhanced glycolysis even in the presence of 
ample oxygen, despite the fact that this generates ATP 
less efficiently than the aerobic processes of respiration 
and oxidative phosphorylation (OXPHOS), which mainly 
occur in mitochondria. Glycolysis, which produces lactate 
from pyruvate, occurs predominantly in the cytoplasm 
and generates ATP more rapidly than respiration, which 
might offer a selective advantage to rapidly growing 
tumor cells. Thus, enhanced glycolysis even under 20% 
oxygen culture conditions is a characteristic property of 
most cancer cells and is known as the Warburg effect. 
Although there have been limited mechanistic insights 
into the relationship between the Warburg effect with the 
well-characterized molecular and genetic events of cellular 
immortalization, we are beginning to accumulate evidence 
suggesting that the two phenomena are linked [176-179]. 
First, the glycolytic flux declines during senescence both 
in murine and human fibroblasts, while the expression 
Figure 3: Metformin-targeted EMT and tumor metabolism: Novel strategy against CSCs. Top. Oncogenic stimuli can 
either induce senescence or EMT, depending on the cellular and microenvironmental context. Conversely, EMT-inducing transcription 
factors can simultaneously suppress oncogene-induced senescence (OIS)-like responses and induce an EMT, both phenomena contributing 
to malignant progression because EMT generates migrating CSCs by directly linking enhanced cellular motility with the maintenance of 
tumor-initiating (stemness) capacity. Bottom. Rather than constituting a feature of malignancy per se, enhanced aerobic glycolysis and 
shifts in cellular metabolism away from mitochondrial respiration are intimately linked to malignancy at the level of CSCs. Enhanced 
glycolysis may play a causal role in the immortality of CSCs by protecting them from the senescent effects of mitochondrial respiration-
induced oxidative stress. Metformin’s ability to concomitantly attenuate the anti-senescence effects of both the EMT program and the ATP-
generating glycolytic metabotype-the Warburg effect- may result in a phenotypic shift that impedes cancer oncogenesis by down-regulating 
self-renewal and proliferation of CSCs. Oncotarget 2011; 2:  896 - 917 907 www.impactjournals.com/oncotarget
of glycolytic enzymes can modulate cellular lifespan in 
mouse embryonic fibroblasts (MEFs) [176, 181]. Second, 
enhanced glycolysis can protect cells from oxidative 
stress and, consequently, avoid senescence triggered by 
oxidative stress [176]. Third, mouse embryonic stem 
cells, immortalized MEFs and iPSCs have surprisingly 
low rates of mitochondrial O2 consumption accompanied 
by a high glycolytic rate. Indeed, the a priori energetic 
infrastructure of somatic cells appears to be a crucial 
molecular feature for pluripotency because enhancing a 
bioenergetic shift from somatic oxidative mitochondria 
toward an alternative ATP-generating glycolytic process 
maximizes the efficiency of somatic reprogramming to 
pluripotency  [179,  182].  Fourth,  enhanced  glycolysis 
plays an important role in the proliferative potential 
of stem cells; accordingly, they are hypersensitive to 
glycolytic inhibition and, once differentiated, they stop 
proliferation and drastically reduce their glycolytic flux. 
Altogether these data support the hypothesis that enhanced 
glycolysis actively protects cells from senescence induced 
by oxidative stress, a metabolic protection that might 
causally contribute to the maintenance of the self-renewal 
capacity of stem cells. The enhanced glycolysis of the 
Warburg effect is a crucial metabolic feature that helps 
bypass senescence, and this may provide indirect evidence 
that metformin’s primary target is the immortalizing step 
during  tumorigenesis  (Fig. 3).  During  immortalization, 
several biological events are required beyond bypassing 
senescence such as growth factor independence, evasion 
of apoptosis, anti-growth signals, etc. If enhanced 
glycolysis is necessary and sufficient to enable indefinite 
proliferation  (i.e.,  immortalization)  very  early  during 
multi-step carcinogenesis in  vivo, then metformin’s 
ability to inhibit the glucose flux while simultaneously 
stimulating  the  lactate/pyruvate  flux  and  mitochondrial 
biogenesis must cause ATP depletion accompanied by 
a drastic increase in cellular AMP, which is expected to 
induce premature senescence [183]. 
Metformin and cancer prevention: Pre-clinical 
evidence
Over the next 5 to 10 years, the results of ongoing 
and planned metformin-based cancer studies will become 
available. Although it is anticipated that they will provide 
clinically relevant information regarding the actual effect 
of metformin on risk and outcomes in many common 
human cancers, pre-clinical studies can still provide crucial 
information on mechanisms of metformin’s anticancer 
activity. These data could potentially facilitate the use of 
metformin as a novel agent for targeted cancer prevention. 
Studies examining the effect of metformin on colorectal 
carcinogenesis in chemically-induced animal models 
have demonstrated that metformin treatment efficiently 
suppresses  azoxymethane-induced  colorectal  aberrant 
crypt foci via the inhibition of the mTOR pathway and 
through the activation of AMPK [184]. Based on these data, 
Hosono et al. [185] recently conducted a pilot clinical trial 
providing evidence that short-term, low-dose metformin 
(250 mg once daily for 1 month versus the typical 500 
mg  three  times  daily  in  type  2  diabetes)  safely  and 
directly suppresses both colorectal epithelial proliferation 
and aberrant crypt formation, an endoscopic surrogate 
marker of colorectal cancer, in prospectively randomized 
nondiabetic patients [185]. The gastrointestinal tract 
may be a special case where metformin appears to act 
locally from the lumen following oral administration; 
this raises the question of whether one could expect more 
enhanced benefits by achieving more continuous exposure 
to  metformin  (e.g.,  using  the  low-release  metformin 
preparations  developed  for  dosing  convenience). 
This  first  reported  trial  demonstrated  the  potential  for 
metformin in the chemoprevention of colorectal cancer. 
These  findings  were  extended  to  lung  tumors  in  the 
tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-
pyridil)-1-butanone  (NNK)-induced  lung  cancer  mouse 
model. Using this model, Memmott et al. [186] recently 
demonstrated that treatment with high-dose metformin 
remarkably  decreased  tumor  burden  (∼70%)  without 
affecting tumor incidence, providing strong rationale for 
clinical prevention trials for lung cancer in heavy smokers. 
While there was no evidence of metformin-induced 
activation  of AMPK  in  lung  tumors,  metformin  led  to 
decreased levels of circulating insulin and IGF as well as 
decreased phosphorylation of IGF-IR, AKT and mTOR 
in tumor tissue. Thus, the profound effects on tumor 
growth may have been a consequence of perturbation of 
glucose homeostasis and hormone levels leading to the 
indirect inhibition of mTOR by decreasing activation of 
IR/IGF-IR and AKT upstream of mTOR. A completely 
different picture was observed in a study with chemically 
induced mammary cancer in female Sprague-Dawley rats. 
Zhu et al. [187] reported that while a dosing regimen of 
1.0%/0.25% metformin was capable of reducing palpable 
mammary carcinoma incidence, multiplicity and tumor 
burden and prolonged latency, lower doses of metformin 
failed to inhibit carcinogenesis despite reducing plasma 
insulin. Notably, metformin appeared to offer protection 
against new tumor occurrence following release from the 
combined treatment of metformin with dietary energy 
restriction.  Because  flow  cytometry  analyses  indicated 
the presence of tumor-initiating cells in chemically 
induced mammary carcinomas, these findings support the 
hypothesis that metformin may be an effective component 
of multi-agent interventions against CSCs [187]. 
METFORMIN: MULTI-FACETED 
PROTECTION AGAINST CANCER
We have reviewed the historic, epidemiological, 
pre-clinical and clinical studies in which the anti-diabetic Oncotarget 2011; 2:  896 - 917 908 www.impactjournals.com/oncotarget
biguanide metformin has suggested its unexpected use 
in oncology. It is unknown whether metformin would 
provide protective effects in people without diabetes, and 
we are still lacking additional physiologically relevant 
experimental models to elucidate whether the effects are 
via direct suppression of mTOR signaling in malignant 
(subclinical) or premalignant cells and/or by decreasing 
the levels of circulating hormones (which may promote the 
growth of malignant cells). However, a number of clinical 
trials examining the use of metformin as a cancer therapy 
are currently underway in prostate, breast, endometrial, 
and pancreatic cancer patients [188-194]. As auspiciously 
suggested  by  Dowling  et  al.  [195],  “the  initiation  of 
new, focused clinical trials containing strong correlative 
science components will be crucial in understanding the 
effects of the drug on a range of cancer patients (including 
non-diabetic patients) and the identification of biomarkers 
that predict metformin benefit and response to therapy.” 
Chemoprevention studies with metformin should ideally 
target patients with a high risk of developing cancers, such 
Figure 4: Metformin lowered threshold for senescence: Better protection and treatment against cancer. With increasing 
levels of senescence-inducing stress (e.g., oncogenes, DNA damage, oxidative damage), tumor development goes through three stages 
namely pre-tumoral, pre-malignant and malignant tumor stages. The stressors normally reach sufficient intensity to trigger senescence 
only at the pre-malignant tumor stage. If the critical point for triggering senescence can be lowered by metformin by promoting DDR-
like signals and/or impeding anti-senescence phenotypes (e.g., EMT, glycolytic metabotypes) in pre-tumoral (top) or tumoral (bottom) 
tissues, metformin treatment could translate into better protection against cancer (i.e., metformin’s cancer prevention modality, top) and 
could impede progression to advanced and metastatic disease (i.e., metformin’s cancer treatment modality, bottom). Our current ability to 
identify pre-malignant lesions has the potential to allow their early detection and treatment with metformin as a pro-senescence modality. 
In a neoadjuvant setting, metformin-induced senescence may reduce tumor growth and trigger the immune system to clear senescent cells, 
contributing to the reduction of tumor burden obtained with traditional chemotherapeutic and radiottherapeutic protocols. Metformin-based 
pro-senescence approaches may be also advantageous in the adjuvant setting, as it may have the ability to reduce the statistical risk of 
relapse from occult disease (e.g., residual disease in lymph nodes or systemic micrometastasis) that could arise from remaining quiescent 
CSCs.Oncotarget 2011; 2:  896 - 917 909 www.impactjournals.com/oncotarget
as those with premalignant conditions (e.g., DCIS of the 
breast, atypical adenomatous hyperplasia of the lung) or 
those with a high risk of disease recurrence (e.g., in the 
adjuvant setting) (Fig. 4). 
If metformin therapy creates an intrinsic barrier 
against tumorigenesis by lowering the threshold for 
stress-induced senescence, metformin therapeutic 
strategies aimed to enhance senescence may be pivotal for 
therapeutic intervention of cancer. To test the hypothesis 
that metformin therapy is a senescence-based cancer 
prevention strategy (Fig. 4, top), we suggest the following 
study  in  women  with  DCIS  lesions.  Given  that  DCIS 
lesions contain pre-existing carcinoma precursor cells, it 
would be of interest to evaluate whether metformin use 
in nondiabetic women reduces the expected progression 
rate (12-15%) of DCIS lesions to invasive breast cancer. 
Taking advantage of previously used trial strategies for 
tamoxifen-based neoadjuvant therapy of DCIS [196], it 
might be reasonable to start a clinical trial for metformin-
based neoadjuvant therapy of DCIS in which metformin 
is administered after diagnosis by a primary biopsy but 
before the commencement of standard-of-cancer surgical 
therapy.  New  contralateral  tumors  in  women  with 
breast cancer might be useful as a model for secondary 
prevention, similar to tamoxifen [197]. If valid, such a 
model would facilitate the testing of metformin therapy 
as a senescence-based cancer treatment strategy (Fig. 4, 
bottom). Taking advantage of previous trials on the anti-
CSC activity of targeted drugs in a neoadjuvant setting 
[198, 199], paired core biopsies could be obtained from 
patients before and after treatment with metformin 
regimens. Cell populations isolated from biopsy samples 
taken before and after metformin-based therapy could 
be assayed for tumor-initiating cells by measuring their 
ability to form mammospheres in vivo, a widely accepted 
indicator of self-renewal. In parallel, the presence of 
senescent cells before and after metformin-based therapy 
could  be  detected  by  the  classical  test  for  SA-β-Gal 
activity  using  X-Gal  (5-bromo-4-chloro-3-indolyl-β-D-
galactoside) [200]. As suggested by Nardella et al. [157], 
this type of analysis may be readily performed on tumor 
biopsy samples, although it should be noted that biopsy 
samples should be frozen for optimal senescence analysis 
[201]. Immunohistochemical analysis of traditional 
senescence effectors (e.g., upregulation of p53, INK4A, 
p21 and p27) can also enable the detection of metformin’s 
ability to induce senescence as part of its therapeutic 
effects. 
Extensive clinical experience with metformin 
coupled with the preclinical rationale, potential 
mechanisms of metformin’s anti-cancer effects and its 
modest toxicity have sped up the timeline of oncology drug 
development (Fig. 1). Indeed, metformin exemplifies how 
systems biology strategies for repositioning regulatory 
agency  (FDA/EMEA)-approved  drugs  may  accelerate 
our ability to prevent and/or treat cancer in a multifaceted 
manner, including elimination of CSCs. We anticipate the 
translational impact that metformin will have as a valuable 
oncology drug due to its ability to arrest carcinomas at 
their  non-invasive,  premalignant  stages.  Current  [107, 
193, 202] and future clinical trials will elucidate whether 
metformin has the potential to be used in both preventive 
and treatment settings as an adjuvant to current cancer 
therapeutics.
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